ClinicalTrials.gg
CompletedNCT02804763Updated Jun 30, 2021Results posted

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

A Phase 2 interventional study of Placebo and Dapirolizumab pegol (DZP) in Systemic Lupus Erythematosus (SLE), sponsored by UCB Biopharma S.P.R.L.. Completed at 71 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.

Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..

Enrollment
10th of 21
182 · median 54
Started
2016
the only one that year
Phase 2
6 of 21
none open now
Registered
16th of 21
by date

Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 10th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 2, and was the 16th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Lupus Erythematosus, Systemic by UCB S.A., or all of them as a file.
02

Study summary

The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • Systemic Lupus Erythematosus (SLE)
  • Dapirolizumab Pegol (DZP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Systemic Lupus Erythematosus (SLE) confirmed by Systemic Lupus International Collaborating Clinics (SLICC) classification criteria
  • Moderate to severe SLE disease activity
  • Evidence for at least 1 of the following SLE markers:

    • Anti-dsDNA antibodies confirmed by central laboratory or
    • Low complement confirmed by central laboratory or
    • Antinuclear antibody (ANA) titer of >= 1:80 in combination with at least 1 of the following: Historical positivity for anti-dsDNA or Positivity for extractable nuclear antigen (anti-ENA) confirmed by central laboratory
  • The subject is receiving stable SLE standard-of-care medication

Exclusion criteria

Exclusion Criteria:

  • Mixed connective tissue disease, scleroderma, and/or overlap syndromes of SLE
  • Subjects with severe neuropsychiatric SLE or other neurological symptoms that in the opinion of the Investigator, would prevent the subject from completing protocol required procedures and assessments.
  • New or worsening Class III or IV lupus nephritis
  • Chronic kidney failure stage 3b
  • Evidence of (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection at any time prior to or during the study
  • active or latent infection (eg. chronic viral or C)
  • Known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent TB (LTB) infection
  • Live/ within 6 weeks prior to the first study drug infusion (Visit 2) or who plan to receive these vaccines during the study or 12 weeks after the final dose of study drug
  • History of thromboembolic events within 12 months of screening
  • Subject has used protocol defined prohibited medications
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo in a specified sequence for a total of 24 weeks

    Drug: Placebo

  • Experimental
    DZP dose 1

    Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks

    Drug: Dapirolizumab pegol (DZP)

  • Experimental
    DZP dose 2

    Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks

    Drug: Dapirolizumab pegol (DZP)

  • Experimental
    DZP dose 3

    Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks

    Drug: Dapirolizumab pegol (DZP)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 24

    The primary efficacy variable was assessed by establishing if there was a dose response relationship between BICLA response at Week 24 and dose, using Multiple Comparison Procedure - Modelling (MCP-Mod). Four candidate dose-response models were evaluated: a linear model, a logistic model, and 2 Emax models, and the MCP-Mod methodology controlled for multiplicity. BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.

    Time frame: Week 24

Secondary outcomes

  1. The Percentage of Participants With BICLA (mNRI) Response in the Individual Dose Groups at Week 24

    BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.

    Time frame: Week 24

  2. Percentage of Participants With at Least One Adverse Events (AEs)

    An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.

    Time frame: From Baseline (Week 1) until end of the study (Week 48)

  3. Percentage of Participants With a Serious Adverse Event (SAE)

    A Serious Adverse Event (SAE) must have met 1 or more of the following criteria: * Death * Life threatening * Significant or persistent disability/incapacity * Congenital anomaly/birth defect (including that occurring in a fetus) * Important medical event that, based upon appropriate medical judgment, may have jeopardized the study participant, and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious * Initial inpatient hospitalization or prolongation of hospitalization.

    Time frame: From Baseline (Week 1) until end of the study (Week 48)

  4. Percentage of Participants With at Least One Adverse Events (AEs) of Interest

    Adverse events of interest (AEOI) were identified by the Investigator based on definitions per protocol, documented on the electronic Case Report Form (eCRF), adequately monitored, and source controlled. AEOI (regardless of seriousness): * Moderate to severe infections, including opportunistic infections and tuberculosis (TB) * Infusion reactions (including hypersensitivity and anaphylaxis) * Thromboembolic events (including but not limited to cardiovascular events, stroke, myocardial infarction, pulmonary embolism, and deep vein thrombosis) * Prespecified neurological events: severe and/or serious headache, positional headache, cranial nerve dysfunction, or signs and symptoms of meningitis (photophobia, neck stiffness) * Malignancies.

    Time frame: From Baseline (Week 1) until end of the study (Week 48)

  5. Percentage of Participants Who Permanently Withdrew of Study Drug Due to an Adverse Event (AE)

    An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.

    Time frame: From Baseline (Week 1) until end of the study (Week 48)

  6. Mean Change From Baseline in Systolic Blood Pressure

    Blood pressure was measured in millimetre of mercury (mmHg).

    Time frame: From Baseline (Week 1) to Week 48

  7. Mean Change From Baseline in Diastolic Blood Pressure

    Blood pressure was measured in millimetre of mercury (mmHg).

    Time frame: From Baseline (Week 1) to Week 48

  8. Mean Change From Baseline in Pulse Rate

    Pulse Rate was measured in beats per minute (beats/min).

    Time frame: From Baseline (Week 1) to Week 48

  9. Mean Change From Baseline in Temperature

    Temperature was measured in Grad Celsius (°C).

    Time frame: From Baseline (Week 1) to Week 48

  10. Mean Change From Baseline in Weight

    Weight was measured in kilograms (kg).

    Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, and Week 20

  11. Mean Change From Baseline in Height

    Height was measured in centimeters (cm).

    Time frame: From Baseline (Week 1) to Week 48

  12. Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormal Findings

    Twelve-lead ECG assessments should have been performed prior to dosing (if applicable) and prior to obtaining pharmacokinetic (PK) or other laboratory samples. Electrocardiograms were recorded digitally and read by the Investigator for recording in the electronic Case Report Form (eCRF).

    Time frame: Screening, Week 4, Week 24, Week 28 and Week 48

  13. Mean Change From Baseline in Hemoglobin

    Hemoglobin was measured in grams per liter (g/L).

    Time frame: From Baseline (Week 1) to Week 48

  14. Mean Change From Baseline in Hematocrit

    Hematocrit was measured in volume percentage (%) of red blood cells in blood.

    Time frame: From Baseline (Week 1) to Week 48

  15. Mean Change From Baseline in Erythrocytes

    Erythrocytes was measured in number of erythrocytes per liter (10\^12/L).

    Time frame: From Baseline (Week 1) to Week 48

  16. Mean Change From Baseline in Erythrocytes Mean Corpuscular Volume

    Erythrocytes Mean Corpuscular Volume was measured in femtolitres (fL).

    Time frame: From Baseline (Week 1) to Week 48

  17. Mean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

    Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration was measured in grams per liter (g/L).

    Time frame: From Baseline (Week 1) to Week 48

  18. Mean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

    Erythrocytes Mean Corpuscular Hemoglobin was measured in picograms (pg).

    Time frame: From Baseline (Week 1) to Week 48

  19. Mean Change From Baseline in Leukocytes

    Leukocytes was measured in number of leukocytes per liter (10\^9/L).

    Time frame: From Baseline (Week 1) to Week 48

  20. Mean Change From Baseline in Basophils

    Basophils was measured in number of basophils per liter (10\^9/L).

    Time frame: From Baseline (Week 1) to Week 48

  21. Mean Change From Baseline in Basophils/Leukocytes

    Basophils/Leukocytes was measured in percentages (%).

    Time frame: From Baseline (Week 1) to Week 48

  22. Mean Change From Baseline in Eosinophils

    Eosinophils was measured in number of eosinophils per liter (10\^9/L).

    Time frame: From Baseline (Week 1) to Week 48

  23. Mean Change From Baseline in Eosinophils/Leukocytes

    Eosinophils/Leukocytes was measured in percentages (%).

    Time frame: From Baseline (Week 1) to Week 48

  24. Mean Change From Baseline in Lymphocytes

    Lymphocytes was measured in number of lymphocytes per liter (10\^9/L).

    Time frame: From Baseline (Week 1) to Week 48

  25. Mean Change From Baseline in Lymphocytes/Leukocytes

    Lymphocytes/Leukocytes was measured in percentages (%).

    Time frame: From Baseline (Week 1) to Week 48

  26. Mean Change From Baseline in Monocytes

    Monocytes was measured in number of monocytes per liter (10\^9/L).

    Time frame: From Baseline (Week 1) to Week 48

  27. Mean Change From Baseline in Monocytes/Leukocytes

    Monocytes/Leukocytes was measured in percentages (%).

    Time frame: From Baseline (Week 1) to Week 48

  28. Mean Change From Baseline in Neutrophils

    Neutrophils was measured in number of neutrophils per liter (10\^9/L).

    Time frame: From Baseline (Week 1) to Week 48

  29. Mean Change From Baseline in Neutrophils/Leukocytes

    Neutrophils/Leukocytes was measured in percentages (%).

    Time frame: From Baseline (Week 1) to Week 48

  30. Mean Change From Baseline in Platelets

    Platelets was measured in number of platelets per liter (10\^9/L).

    Time frame: From Baseline (Week 1) to Week 48

  31. Mean Change From Baseline in Cluster of Differentiation 3 (CD3)

    Cluster of differentiation 3 (CD3) was measured in cells per microliter (cells/µL).

    Time frame: From Baseline (Week 1) to Week 48

  32. Mean Change From Baseline in CD3/Lymphocytes

    CD3/Lymphocytes was measured in percentages (%).

    Time frame: From Baseline (Week 1) to Week 48

  33. Mean Change From Baseline in Cluster of Differentiation 19 (CD19)

    Cluster of differentiation 19 (CD19) was measured in cells per microliter (cells/µL).

    Time frame: From Baseline (Week 1) to Week 48

  34. Mean Change From Baseline in CD19/Lymphocytes

    CD19/Lymphocytes was measured in percentages (%).

    Time frame: From Baseline (Week 1) to Week 48

  35. Mean Change From Baseline in Aspartate Aminotransferase

    Aspartate Aminotransferase was measured in units per liter (U/L).

    Time frame: From Baseline (Week 1) to Week 48

  36. Mean Change From Baseline in Alanine Aminotransferase

    Alanine Aminotransferase was measured in units per liter (U/L).

    Time frame: From Baseline (Week 1) to Week 48

  37. Mean Change From Baseline in Alkaline Phosphatase

    Alkaline Phosphatase was measured in units per liter (U/L).

    Time frame: From Baseline (Week 1) to Week 48

  38. Mean Change From Baseline in Gamma Glutamyl Transferase

    Gamma Glutamyl Transferase was measured in units per liter (U/L).

    Time frame: From Baseline (Week 1) to Week 48

  39. Mean Change From Baseline in Bilirubin

    Bilirubin was measured in micromols per liter (µmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  40. Mean Change From Baseline in Direct Bilirubin

    Direct Bilirubin was measured in micromols per liter (µmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  41. Mean Change From Baseline in Lactate Dehydrogenase

    Lactate Dehydrogenase was measured in units per liter (U/L).

    Time frame: From Baseline (Week 1) to Week 48

  42. Mean Change From Baseline in Creatinine

    Creatinine was measured in micromols per liter (µmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  43. Mean Change From Baseline in Urea Nitrogen

    Urea Nitrogen was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  44. Mean Change From Baseline in Sodium

    Sodium was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  45. Mean Change From Baseline in Potassium

    Potassium was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  46. Mean Change From Baseline in Calcium

    Calcium was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  47. Mean Change From Baseline in Phosphate

    Phosphate was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  48. Mean Change From Baseline in Cholesterol

    Cholesterol was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  49. Mean Change From Baseline in Triglycerides

    Triglycerides was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  50. Mean Change From Baseline in Protein

    Protein was measured in grams per liter (g/L).

    Time frame: From Baseline (Week 1) to Week 48

  51. Mean Change From Baseline in Albumin

    Albumin was measured in grams per liter (g/L).

    Time frame: From Baseline (Week 1) to Week 48

  52. Mean Change From Baseline in Glucose

    Glucose was measured in millimoles per liter (mmol/L).

    Time frame: From Baseline (Week 1) to Week 48

  53. Mean Change From Baseline in Lipase, Pancreatic

    Lipase, Pancreatic was measured in units per liter (U/L).

    Time frame: From Baseline (Week 1) to Week 48

  54. Mean Change From Baseline in Creatine Kinase

    Creatine Kinase was measured in units per liter (U/L).

    Time frame: From Baseline (Week 1) to Week 48

  55. Mean Change From Baseline in pH

    Time frame: From Baseline (Week 1) to Week 48

  56. Mean Change From Baseline in Erythrocytes (/HPF)

    Time frame: From Baseline (Week 1) to Week 48

  57. Mean Change From Baseline in Leukocytes (/HPF)

    Time frame: From Baseline (Week 1) to Week 48

07

Results

Posted Jun 30, 2021

Participant flow

The study started to enroll patients in June 2016 and concluded in November 2018.

Double-Blind Period (Week 1 to Week 24)
Participant flow — Double-Blind Period (Week 1 to Week 24)
MilestoneSOC + Placebo iv Q4WSOC + DZP 6mg/kg iv Q4WSOC + DZP 24mg/kg iv Q4WSOC + DZP 45mg/kg iv Q4W
Started45454547
Completed week 2444454445
Finished wk24 began observational period44444445
Completed44444445
Not completed1112
Withdrew: Adverse event1000
Withdrew: Withdrawal by subject0012
Withdrew: Consent withdrawal after week 240100
Observational Period (Wk 24 to Wk 48)
Participant flow — Observational Period (Wk 24 to Wk 48)
MilestoneSOC + Placebo iv Q4WSOC + DZP 6mg/kg iv Q4WSOC + DZP 24mg/kg iv Q4WSOC + DZP 45mg/kg iv Q4W
Started44444445
Completed38434142
Not completed6133
Withdrew: Lost to follow-up2011
Withdrew: Withdrawal by subject4022
Withdrew: Patient moved out of state0100

Outcome measures

PrimaryPercentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 24

The primary efficacy variable was assessed by establishing if there was a dose response relationship between BICLA response at Week 24 and dose, using Multiple Comparison Procedure - Modelling (MCP-Mod). Four candidate dose-response models were evaluated: a linear model, a logistic model, and 2 Emax models, and the MCP-Mod methodology controlled for multiplicity. BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 24
percentage of participantsSOC + Placebo iv Q4W (FAS)SOC + DZP 6mg/kg iv Q4W (FAS)SOC + DZP 24mg/kg iv Q4W (FAS)SOC + DZP 45mg/kg iv Q4W (FAS)
Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 240000
Statistical analysis
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 6mg/kg iv Q4W (FAS) vs SOC + DZP 24mg/kg iv Q4W (FAS) vs SOC + DZP 45mg/kg iv Q4W (FAS) · MCP-Mod · p = =0.0727 (The lowest p-value (z-statistic with the highest value) was used to establish proof of dose response.)
SecondaryThe Percentage of Participants With BICLA (mNRI) Response in the Individual Dose Groups at Week 24

BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.

Time frame:
Week 24
Reported as:
Number · percentage of participants
The Percentage of Participants With BICLA (mNRI) Response in the Individual Dose Groups at Week 24
percentage of participantsSOC + Placebo iv Q4W (FAS)SOC + DZP 6mg/kg iv Q4W (FAS)SOC + DZP 24mg/kg iv Q4W (FAS)SOC + DZP 45mg/kg iv Q4W (FAS)
The Percentage of Participants With BICLA (mNRI) Response in the Individual Dose Groups at Week 2437.248.854.552.2
Statistical analysis
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 6mg/kg iv Q4W (FAS) · Chi-squared · p = =0.2699 (Generalized linear models with factors for treatment and corticosteroid strata were fit using a logit link function for the odds ratios and p-values.) · Odds ratio (or): 1.6 · 95% CI 0.7 to 3.8
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 24mg/kg iv Q4W (FAS) · Chi-squared · p = =0.1036 (Generalized linear models with factors for treatment and corticosteroid strata were fit using a logit link function for the odds ratios and p-values.) · Odds ratio (or): 2.0 · 95% CI 0.9 to 4.8
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 45mg/kg iv Q4W (FAS) · Chi-squared · p = =0.1518 (Generalized linear models with factors for treatment and corticosteroid strata were fit using a logit link function for the odds ratios and p-values.) · Odds ratio (or): 1.9 · 95% CI 0.8 to 4.3
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 6mg/kg iv Q4W (FAS) · Chi-squared · Difference vs pbo: 11.6 · 95% CI -9.2 to 32.4Difference and 95 % Wald CI in proportion of responders for SOC + DZP dose 1 iv Q4W (FAS) versus SOC + Placebo iv Q4W (FAS).
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 24mg/kg iv Q4W (FAS) · Chi-squared · Difference vs pbo: 17.3 · 95% CI -3.3 to 38.0Difference and 95 % Wald CI in proportion of responders for SOC + DZP dose 2 iv Q4W (FAS) versus SOC + Placebo iv Q4W (FAS).
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 45mg/kg iv Q4W (FAS) · Chi-squared · Difference vs pbo: 15.0 · 95% CI -5.5 to 35.4Difference and 95 % Wald CI in proportion of responders for SOC + DZP dose 3 iv Q4W (FAS) versus SOC + Placebo iv Q4W (FAS).
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 6mg/kg iv Q4W (FAS) · Chi-squared · Ls mean difference vs pbo: 11.9 · 95% CI -8.7 to 32.5
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 24mg/kg iv Q4W (FAS) · Chi-squared · Ls mean difference vs pbo: 17.6 · 95% CI -3.2 to 38.3
  • SOC + Placebo iv Q4W (FAS) vs SOC + DZP 45mg/kg iv Q4W (FAS) · Chi-squared · Ls mean difference vs pbo: 15.2 · 95% CI -5.2 to 35.6
SecondaryPercentage of Participants With at Least One Adverse Events (AEs)

An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.

Time frame:
From Baseline (Week 1) until end of the study (Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Events (AEs)
percentage of participantsSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Percentage of Participants With at Least One Adverse Events (AEs)66.766.782.274.5
SecondaryPercentage of Participants With a Serious Adverse Event (SAE)

A Serious Adverse Event (SAE) must have met 1 or more of the following criteria: * Death * Life threatening * Significant or persistent disability/incapacity * Congenital anomaly/birth defect (including that occurring in a fetus) * Important medical event that, based upon appropriate medical judgment, may have jeopardized the study participant, and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious * Initial inpatient hospitalization or prolongation of hospitalization.

Time frame:
From Baseline (Week 1) until end of the study (Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With a Serious Adverse Event (SAE)
percentage of participantsSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Percentage of Participants With a Serious Adverse Event (SAE)13.311.113.310.6
SecondaryPercentage of Participants With at Least One Adverse Events (AEs) of Interest

Adverse events of interest (AEOI) were identified by the Investigator based on definitions per protocol, documented on the electronic Case Report Form (eCRF), adequately monitored, and source controlled. AEOI (regardless of seriousness): * Moderate to severe infections, including opportunistic infections and tuberculosis (TB) * Infusion reactions (including hypersensitivity and anaphylaxis) * Thromboembolic events (including but not limited to cardiovascular events, stroke, myocardial infarction, pulmonary embolism, and deep vein thrombosis) * Prespecified neurological events: severe and/or serious headache, positional headache, cranial nerve dysfunction, or signs and symptoms of meningitis (photophobia, neck stiffness) * Malignancies.

Time frame:
From Baseline (Week 1) until end of the study (Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Events (AEs) of Interest
percentage of participantsSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Percentage of Participants With at Least One Adverse Events (AEs) of Interest24.426.728.925.5
SecondaryPercentage of Participants Who Permanently Withdrew of Study Drug Due to an Adverse Event (AE)

An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.

Time frame:
From Baseline (Week 1) until end of the study (Week 48)
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Withdrew of Study Drug Due to an Adverse Event (AE)
percentage of participantsSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Percentage of Participants Who Permanently Withdrew of Study Drug Due to an Adverse Event (AE)8.904.44.3
SecondaryMean Change From Baseline in Systolic Blood Pressure

Blood pressure was measured in millimetre of mercury (mmHg).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic Blood Pressure
mmHgSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 23.3 ± 12.95.1 ± 10.50.7 ± 10.73.2 ± 9.9
Week 40.6 ± 10.81.0 ± 7.9-2.0 ± 8.90.6 ± 12.4
Week 60.3 ± 11.54.0 ± 9.92.3 ± 11.02.4 ± 10.6
Week 80.5 ± 12.43.3 ± 12.6-2.4 ± 9.9-0.7 ± 11.9
Week 12-0.7 ± 10.13.2 ± 10.5-3.0 ± 11.80.8 ± 9.2
Week 162.1 ± 12.32.1 ± 11.6-2.8 ± 10.60.9 ± 11.1
Week 201.6 ± 9.92.6 ± 9.8-1.7 ± 12.31.5 ± 11.3
Week 24-0.7 ± 14.31.1 ± 13.10.3 ± 11.03.6 ± 9.3
Week 281.8 ± 12.33.7 ± 13.10.9 ± 10.52.5 ± 11.8
Week 322.2 ± 11.13.0 ± 13.20.4 ± 11.34.3 ± 13.7
Week 362.1 ± 11.03.1 ± 12.60.2 ± 10.52.4 ± 12.9
Week 40-1.0 ± 14.16.2 ± 12.9-2.0 ± 11.72.5 ± 11.3
Week 440.1 ± 12.63.3 ± 14.11.3 ± 10.44.2 ± 11.8
Week 48-1.5 ± 11.54.9 ± 14.30.1 ± 10.24.4 ± 12.0
SecondaryMean Change From Baseline in Diastolic Blood Pressure

Blood pressure was measured in millimetre of mercury (mmHg).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmHg
Mean Change From Baseline in Diastolic Blood Pressure
mmHgSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 22.1 ± 10.51.4 ± 8.61.5 ± 9.32.4 ± 8.2
Week 4-0.7 ± 7.8-1.5 ± 6.3-1.7 ± 8.2-0.1 ± 8.3
Week 61.0 ± 10.01.5 ± 8.61.8 ± 10.01.9 ± 7.9
Week 81.1 ± 9.20.4 ± 9.10.1 ± 8.61.0 ± 8.0
Week 12-0.9 ± 8.4-0.3 ± 6.9-2.2 ± 9.6-0.3 ± 6.9
Week 16-0.3 ± 8.9-1.3 ± 7.6-0.7 ± 9.5-0.1 ± 7.0
Week 201.5 ± 8.1-1.1 ± 8.7-0.7 ± 9.60.9 ± 8.8
Week 241.9 ± 11.21.6 ± 8.72.3 ± 10.70.6 ± 8.7
Week 281.5 ± 9.1-0.2 ± 8.81.4 ± 8.42.5 ± 8.4
Week 322.3 ± 10.12.8 ± 9.30.7 ± 10.22.3 ± 8.1
Week 363.4 ± 9.81.4 ± 10.21.4 ± 8.42.2 ± 8.0
Week 401.0 ± 9.22.6 ± 7.60.5 ± 9.93.6 ± 8.8
Week 440.8 ± 10.21.5 ± 8.10.4 ± 9.42.2 ± 10.3
Week 481.4 ± 9.02.3 ± 8.81.1 ± 9.42.4 ± 8.6
SecondaryMean Change From Baseline in Pulse Rate

Pulse Rate was measured in beats per minute (beats/min).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · beats/min
Mean Change From Baseline in Pulse Rate
beats/minSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.2 ± 8.30.2 ± 10.42.3 ± 9.7-0.9 ± 10.4
Week 41.7 ± 9.61.5 ± 8.00.4 ± 8.4-3.3 ± 9.7
Week 6-0.7 ± 10.20.1 ± 8.50.8 ± 8.9-0.6 ± 8.8
Week 81.3 ± 9.00.3 ± 9.21.4 ± 10.2-2.6 ± 10.2
Week 120.6 ± 10.31.1 ± 9.8-0.3 ± 10.4-1.5 ± 9.7
Week 16-0.8 ± 9.20.3 ± 8.90.9 ± 10.7-1.6 ± 10.6
Week 200.3 ± 10.61.1 ± 9.90.8 ± 9.50.4 ± 6.6
Week 24-1.5 ± 10.70.8 ± 10.9-0.3 ± 10.2-1.0 ± 8.7
Week 280.6 ± 11.81.3 ± 10.90.0 ± 9.20.6 ± 8.8
Week 320.4 ± 9.81.3 ± 10.90.8 ± 11.4-2.1 ± 11.0
Week 36-0.7 ± 10.90.2 ± 8.30.7 ± 10.4-0.2 ± 9.8
Week 40-0.1 ± 10.9-0.1 ± 9.80.6 ± 10.2-1.3 ± 9.6
Week 44-0.2 ± 10.2-0.1 ± 9.80.3 ± 11.7-0.6 ± 8.9
Week 48-0.2 ± 11.1-0.7 ± 10.6-0.9 ± 11.9-2.0 ± 7.7
SecondaryMean Change From Baseline in Temperature

Temperature was measured in Grad Celsius (°C).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · Temperature (C)
Mean Change From Baseline in Temperature
Temperature (C)SOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.1 ± 0.40.0 ± 0.30.1 ± 0.50.0 ± 0.4
Week 4-0.1 ± 0.40.0 ± 0.40.0 ± 0.40.0 ± 0.3
Week 6-0.2 ± 0.50.0 ± 0.40.1 ± 0.50.0 ± 0.5
Week 8-0.1 ± 0.4-0.1 ± 0.30.0 ± 0.40.0 ± 0.4
Week 12-0.1 ± 0.4-0.1 ± 0.40.0 ± 0.30.0 ± 0.4
Week 16-0.1 ± 0.40.0 ± 0.40.0 ± 0.40.0 ± 0.3
Week 20-0.1 ± 0.40.0 ± 0.40.0 ± 0.40.0 ± 0.5
Week 24-0.1 ± 0.50.0 ± 0.40.1 ± 0.50.0 ± 0.4
Week 280.0 ± 0.40.0 ± 0.40.1 ± 0.50.1 ± 0.5
Week 320.0 ± 0.40.0 ± 0.40.1 ± 0.50.0 ± 0.4
Week 36-0.1 ± 0.30.0 ± 0.60.0 ± 0.40.1 ± 0.4
Week 400.0 ± 0.40.0 ± 0.40.0 ± 0.50.1 ± 0.3
Week 440.0 ± 0.60.0 ± 0.50.1 ± 0.40.0 ± 0.4
Week 48-0.1 ± 0.40.0 ± 0.40.0 ± 0.50.0 ± 0.4
SecondaryMean Change From Baseline in Weight

Weight was measured in kilograms (kg).

Time frame:
Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, and Week 20
Reported as:
Mean · kg
Mean Change From Baseline in Weight
kgSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 40.0 ± 1.00.2 ± 1.00.4 ± 0.90.3 ± 1.2
Week 80.3 ± 1.90.6 ± 1.40.6 ± 1.80.4 ± 1.8
Week 120.4 ± 2.30.5 ± 1.60.5 ± 2.00.6 ± 2.3
Week 160.3 ± 2.30.7 ± 2.30.8 ± 2.30.5 ± 2.4
Week 200.3 ± 2.40.7 ± 2.61.0 ± 2.60.5 ± 2.8
SecondaryMean Change From Baseline in Height

Height was measured in centimeters (cm).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · cm
Mean Change From Baseline in Height
cmSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Mean Change From Baseline in HeightNA ± NANA ± NANA ± NANA ± NA
SecondaryNumber of Participants With 12-Lead Electrocardiogram (ECG) Abnormal Findings

Twelve-lead ECG assessments should have been performed prior to dosing (if applicable) and prior to obtaining pharmacokinetic (PK) or other laboratory samples. Electrocardiograms were recorded digitally and read by the Investigator for recording in the electronic Case Report Form (eCRF).

Time frame:
Screening, Week 4, Week 24, Week 28 and Week 48
Reported as:
Count of participants · Participants
Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormal Findings
ParticipantsSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Screening81166
Week 41112710
Week 2497610
Week 281000
Week 4887119
SecondaryMean Change From Baseline in Hemoglobin

Hemoglobin was measured in grams per liter (g/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · g/L
Mean Change From Baseline in Hemoglobin
g/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.4 ± 6.4-1.8 ± 5.8-0.7 ± 6.9-0.7 ± 6.8
Week 4-1.0 ± 7.2-0.7 ± 7.7-1.4 ± 8.6-0.8 ± 5.8
Week 8-0.3 ± 7.3-1.9 ± 7.9-1.9 ± 8.6-1.3 ± 7.4
Week 12-0.5 ± 9.5-0.5 ± 8.5-0.5 ± 10.10.2 ± 8.3
Week 160.3 ± 10.4-0.3 ± 10.0-0.8 ± 10.6-2.7 ± 8.3
Week 20-0.7 ± 11.50.3 ± 9.9-0.5 ± 10.1-2.4 ± 7.2
Week 24-0.4 ± 9.7-0.7 ± 11.2-0.7 ± 10.5-2.9 ± 8.1
Week 280.7 ± 10.6-3.4 ± 11.00.0 ± 14.1-3.1 ± 9.5
Week 321.6 ± 12.5-1.3 ± 9.81.0 ± 12.5-1.3 ± 9.6
Week 400.7 ± 13.5-0.3 ± 13.51.9 ± 14.91.1 ± 11.0
Week 48-0.5 ± 14.3-1.5 ± 11.60.9 ± 12.5-0.7 ± 10.0
SecondaryMean Change From Baseline in Hematocrit

Hematocrit was measured in volume percentage (%) of red blood cells in blood.

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · volume % of red blood cells
Mean Change From Baseline in Hematocrit
volume % of red blood cellsSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.42 ± 2.52-0.25 ± 2.26-0.32 ± 2.370.00 ± 2.71
Week 4-0.46 ± 2.29-0.17 ± 2.75-0.79 ± 2.92-0.11 ± 2.31
Week 8-0.27 ± 2.23-0.12 ± 2.94-0.86 ± 2.72-0.42 ± 2.31
Week 12-0.23 ± 2.67-0.13 ± 2.72-0.32 ± 3.39-0.02 ± 2.54
Week 16-0.12 ± 2.860.05 ± 3.25-0.57 ± 3.32-0.84 ± 2.95
Week 20-0.41 ± 3.200.13 ± 2.99-0.42 ± 3.32-0.80 ± 2.83
Week 24-0.09 ± 2.61-0.40 ± 3.19-0.29 ± 3.14-0.76 ± 2.33
Week 280.03 ± 2.98-1.02 ± 3.23-0.22 ± 3.99-0.89 ± 2.47
Week 320.29 ± 2.89-0.62 ± 2.860.17 ± 3.43-0.21 ± 2.82
Week 40-0.20 ± 3.32-0.24 ± 4.370.58 ± 4.110.37 ± 2.72
Week 48-0.59 ± 3.51-0.37 ± 3.58-0.08 ± 3.21-0.11 ± 2.54
SecondaryMean Change From Baseline in Erythrocytes

Erythrocytes was measured in number of erythrocytes per liter (10\^12/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^12 erythrocytes per liter
Mean Change From Baseline in Erythrocytes
10^12 erythrocytes per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.004 ± 0.246-0.035 ± 0.237-0.032 ± 0.223-0.028 ± 0.237
Week 4-0.080 ± 0.243-0.018 ± 0.293-0.052 ± 0.273-0.033 ± 0.210
Week 8-0.039 ± 0.224-0.039 ± 0.280-0.069 ± 0.262-0.044 ± 0.242
Week 12-0.024 ± 0.2710.014 ± 0.292-0.010 ± 0.2670.019 ± 0.226
Week 16-0.002 ± 0.3120.041 ± 0.3600.000 ± 0.302-0.051 ± 0.265
Week 20-0.029 ± 0.3330.062 ± 0.309-0.001 ± 0.325-0.047 ± 0.302
Week 240.005 ± 0.3080.036 ± 0.3120.013 ± 0.319-0.038 ± 0.240
Week 280.018 ± 0.340-0.040 ± 0.3040.019 ± 0.346-0.050 ± 0.270
Week 320.048 ± 0.3200.001 ± 0.2840.032 ± 0.2890.027 ± 0.277
Week 40-0.005 ± 0.3430.042 ± 0.3820.054 ± 0.3680.060 ± 0.256
Week 48-0.024 ± 0.332-0.018 ± 0.2950.017 ± 0.299-0.028 ± 0.245
SecondaryMean Change From Baseline in Erythrocytes Mean Corpuscular Volume

Erythrocytes Mean Corpuscular Volume was measured in femtolitres (fL).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · Femtolitres (fL)
Mean Change From Baseline in Erythrocytes Mean Corpuscular Volume
Femtolitres (fL)SOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 21.01 ± 2.280.24 ± 2.40-0.09 ± 2.660.45 ± 2.96
Week 40.60 ± 2.350.08 ± 2.66-0.68 ± 2.100.40 ± 3.02
Week 80.23 ± 3.48-0.30 ± 5.36-0.54 ± 2.85-0.16 ± 2.79
Week 120.06 ± 3.57-0.52 ± 3.44-0.55 ± 4.67-0.57 ± 3.09
Week 16-0.25 ± 3.41-0.65 ± 4.38-1.38 ± 4.87-0.97 ± 3.62
Week 20-0.37 ± 3.73-0.92 ± 4.58-1.00 ± 5.01-0.97 ± 3.54
Week 24-0.23 ± 3.83-1.63 ± 4.07-0.92 ± 6.51-1.05 ± 4.00
Week 28-0.33 ± 3.61-1.40 ± 4.61-0.96 ± 6.46-1.21 ± 4.91
Week 32-0.27 ± 4.45-1.33 ± 4.32-0.45 ± 6.81-1.06 ± 4.69
Week 40-0.36 ± 5.34-1.46 ± 4.720.07 ± 6.27-0.24 ± 4.85
Week 48-0.98 ± 5.34-0.50 ± 4.97-0.63 ± 6.920.34 ± 4.31
SecondaryMean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration was measured in grams per liter (g/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · g/L
Mean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
g/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-2.3 ± 9.8-2.6 ± 10.90.7 ± 9.8-1.9 ± 10.1
Week 41.4 ± 8.7-0.9 ± 10.12.7 ± 8.6-1.2 ± 12.5
Week 81.7 ± 11.5-3.8 ± 13.42.1 ± 8.2-0.1 ± 11.5
Week 120.5 ± 11.1-0.6 ± 10.70.6 ± 12.30.5 ± 12.7
Week 161.6 ± 13.8-1.5 ± 10.12.3 ± 11.3-0.2 ± 14.1
Week 201.6 ± 12.9-0.9 ± 11.32.4 ± 11.20.4 ± 12.6
Week 240.0 ± 13.71.0 ± 13.20.4 ± 12.8-1.2 ± 13.1
Week 281.6 ± 13.4-1.3 ± 14.41.7 ± 13.8-0.6 ± 16.5
Week 321.7 ± 18.91.1 ± 13.81.2 ± 15.0-1.4 ± 16.0
Week 403.4 ± 17.60.8 ± 16.50.1 ± 15.80.1 ± 15.4
Week 483.6 ± 17.1-0.6 ± 16.22.9 ± 14.50.0 ± 13.5
SecondaryMean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

Erythrocytes Mean Corpuscular Hemoglobin was measured in picograms (pg).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · Picograms (pg)
Mean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
Picograms (pg)SOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.12 ± 0.71-0.18 ± 0.650.04 ± 0.430.00 ± 0.47
Week 40.31 ± 0.63-0.06 ± 0.790.04 ± 0.640.02 ± 0.65
Week 80.20 ± 0.87-0.25 ± 0.870.04 ± 0.81-0.04 ± 0.74
Week 120.04 ± 1.08-0.25 ± 1.03-0.09 ± 1.25-0.12 ± 0.90
Week 160.03 ± 1.43-0.36 ± 1.31-0.20 ± 1.52-0.31 ± 1.19
Week 200.00 ± 1.49-0.39 ± 1.40-0.10 ± 1.63-0.26 ± 1.24
Week 24-0.13 ± 1.57-0.43 ± 1.39-0.25 ± 1.96-0.44 ± 1.42
Week 280.01 ± 1.68-0.55 ± 1.45-0.15 ± 2.09-0.44 ± 1.68
Week 320.01 ± 2.12-0.33 ± 1.28-0.06 ± 2.39-0.48 ± 1.63
Week 400.17 ± 2.50-0.40 ± 1.300.03 ± 2.32-0.09 ± 2.00
Week 480.02 ± 2.58-0.21 ± 1.480.06 ± 2.550.10 ± 1.90
SecondaryMean Change From Baseline in Leukocytes

Leukocytes was measured in number of leukocytes per liter (10\^9/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^9 leukocytes per liter
Mean Change From Baseline in Leukocytes
10^9 leukocytes per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.34 ± 2.450.27 ± 1.230.49 ± 1.460.20 ± 1.62
Week 40.10 ± 1.880.27 ± 1.630.25 ± 1.470.52 ± 2.11
Week 8-0.25 ± 2.120.46 ± 1.41-0.05 ± 1.50-0.10 ± 1.65
Week 12-0.27 ± 1.800.18 ± 1.730.17 ± 2.000.23 ± 2.01
Week 16-0.31 ± 2.180.13 ± 1.550.21 ± 1.69-0.20 ± 2.12
Week 20-0.24 ± 2.27-0.06 ± 1.59-0.22 ± 1.740.30 ± 2.61
Week 24-0.22 ± 2.41-0.12 ± 1.83-0.14 ± 1.75-0.34 ± 1.97
Week 280.05 ± 2.040.06 ± 1.930.26 ± 2.04-0.58 ± 1.70
Week 32-0.14 ± 2.200.08 ± 1.640.19 ± 1.67-0.44 ± 1.68
Week 400.17 ± 2.540.04 ± 1.60-0.35 ± 1.49-0.49 ± 1.96
Week 48-0.49 ± 1.830.30 ± 1.53-0.14 ± 2.06-0.62 ± 1.87
SecondaryMean Change From Baseline in Basophils

Basophils was measured in number of basophils per liter (10\^9/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^9 basophils per liter
Mean Change From Baseline in Basophils
10^9 basophils per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.01 ± 0.030.02 ± 0.040.00 ± 0.030.00 ± 0.02
Week 40.01 ± 0.030.00 ± 0.030.01 ± 0.040.00 ± 0.02
Week 80.01 ± 0.040.01 ± 0.040.01 ± 0.030.00 ± 0.02
Week 120.01 ± 0.030.01 ± 0.040.00 ± 0.030.00 ± 0.03
Week 160.01 ± 0.040.00 ± 0.030.01 ± 0.030.00 ± 0.03
Week 200.00 ± 0.030.01 ± 0.030.00 ± 0.030.00 ± 0.03
Week 240.00 ± 0.030.02 ± 0.040.00 ± 0.030.00 ± 0.03
Week 280.02 ± 0.050.01 ± 0.040.00 ± 0.020.00 ± 0.03
Week 320.00 ± 0.030.00 ± 0.020.01 ± 0.030.00 ± 0.03
Week 400.00 ± 0.020.00 ± 0.020.01 ± 0.030.00 ± 0.03
Week 480.00 ± 0.030.00 ± 0.020.00 ± 0.030.01 ± 0.03
SecondaryMean Change From Baseline in Basophils/Leukocytes

Basophils/Leukocytes was measured in percentages (%).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of Basophils per Leukocytes
Mean Change From Baseline in Basophils/Leukocytes
% of Basophils per LeukocytesSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.05 ± 0.230.02 ± 0.20-0.05 ± 0.31-0.03 ± 0.27
Week 40.03 ± 0.27-0.06 ± 0.26-0.01 ± 0.43-0.07 ± 0.26
Week 80.08 ± 0.420.03 ± 0.320.00 ± 0.33-0.06 ± 0.23
Week 120.04 ± 0.300.09 ± 0.480.00 ± 0.25-0.07 ± 0.28
Week 160.01 ± 0.250.00 ± 0.28-0.02 ± 0.31-0.05 ± 0.30
Week 20-0.02 ± 0.260.00 ± 0.27-0.07 ± 0.29-0.04 ± 0.32
Week 24-0.04 ± 0.310.15 ± 0.44-0.03 ± 0.24-0.03 ± 0.21
Week 280.08 ± 0.540.03 ± 0.290.00 ± 0.240.07 ± 0.32
Week 32-0.03 ± 0.290.00 ± 0.230.01 ± 0.250.01 ± 0.25
Week 40-0.08 ± 0.24-0.03 ± 0.250.07 ± 0.290.01 ± 0.29
Week 48-0.01 ± 0.29-0.08 ± 0.210.02 ± 0.250.06 ± 0.28
SecondaryMean Change From Baseline in Eosinophils

Eosinophils was measured in number of eosinophils per liter (10\^9/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^9 eosinophils per liter
Mean Change From Baseline in Eosinophils
10^9 eosinophils per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.01 ± 0.040.01 ± 0.060.00 ± 0.09-0.01 ± 0.05
Week 4-0.01 ± 0.04-0.01 ± 0.060.00 ± 0.04-0.01 ± 0.04
Week 8-0.01 ± 0.040.03 ± 0.160.00 ± 0.040.01 ± 0.07
Week 120.00 ± 0.040.04 ± 0.200.02 ± 0.100.02 ± 0.17
Week 160.00 ± 0.050.02 ± 0.110.01 ± 0.050.00 ± 0.06
Week 200.00 ± 0.050.04 ± 0.240.01 ± 0.05-0.01 ± 0.05
Week 24-0.01 ± 0.050.04 ± 0.150.02 ± 0.07-0.02 ± 0.06
Week 28-0.01 ± 0.040.01 ± 0.070.01 ± 0.050.00 ± 0.06
Week 32-0.01 ± 0.060.01 ± 0.100.01 ± 0.05-0.02 ± 0.04
Week 400.00 ± 0.050.01 ± 0.060.02 ± 0.060.00 ± 0.07
Week 480.00 ± 0.04-0.01 ± 0.050.00 ± 0.060.00 ± 0.06
SecondaryMean Change From Baseline in Eosinophils/Leukocytes

Eosinophils/Leukocytes was measured in percentages (%).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of Eosinophils per Leukocytes
Mean Change From Baseline in Eosinophils/Leukocytes
% of Eosinophils per LeukocytesSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.19 ± 1.070.07 ± 0.86-0.18 ± 1.13-0.29 ± 1.22
Week 4-0.32 ± 0.96-0.05 ± 1.26-0.12 ± 1.01-0.26 ± 0.94
Week 8-0.05 ± 1.090.54 ± 2.130.10 ± 1.110.22 ± 1.89
Week 120.18 ± 1.030.70 ± 3.120.33 ± 1.680.05 ± 1.83
Week 160.06 ± 1.050.36 ± 1.240.20 ± 1.40-0.11 ± 1.33
Week 200.04 ± 1.110.83 ± 3.580.11 ± 1.24-0.39 ± 1.29
Week 240.11 ± 1.160.82 ± 2.89-0.01 ± 1.220.06 ± 1.63
Week 280.06 ± 1.000.21 ± 1.330.18 ± 1.02-0.03 ± 1.35
Week 320.02 ± 1.090.28 ± 1.600.16 ± 1.13-0.20 ± 1.03
Week 40-0.10 ± 0.850.05 ± 1.090.40 ± 1.23-0.09 ± 1.47
Week 480.09 ± 1.02-0.17 ± 1.080.06 ± 0.900.24 ± 1.03
SecondaryMean Change From Baseline in Lymphocytes

Lymphocytes was measured in number of lymphocytes per liter (10\^9/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^9 lymphocytes per liter
Mean Change From Baseline in Lymphocytes
10^9 lymphocytes per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.03 ± 0.390.05 ± 0.360.16 ± 0.290.24 ± 0.37
Week 4-0.04 ± 0.36-0.01 ± 0.47-0.01 ± 0.410.23 ± 0.42
Week 8-0.15 ± 0.48-0.03 ± 0.390.06 ± 0.460.14 ± 0.50
Week 12-0.06 ± 0.430.02 ± 0.590.01 ± 0.420.21 ± 0.51
Week 16-0.09 ± 0.52-0.11 ± 0.51-0.02 ± 0.470.04 ± 0.40
Week 20-0.14 ± 0.56-0.13 ± 0.540.02 ± 0.390.13 ± 0.55
Week 24-0.11 ± 0.51-0.08 ± 0.60-0.03 ± 0.450.05 ± 0.52
Week 28-0.04 ± 0.57-0.02 ± 0.590.01 ± 0.530.03 ± 0.56
Week 32-0.11 ± 0.57-0.16 ± 0.590.05 ± 0.45-0.02 ± 0.44
Week 40-0.11 ± 0.54-0.11 ± 0.52-0.11 ± 0.43-0.03 ± 0.48
Week 48-0.19 ± 0.68-0.19 ± 0.60-0.10 ± 0.44-0.02 ± 0.49
SecondaryMean Change From Baseline in Lymphocytes/Leukocytes

Lymphocytes/Leukocytes was measured in percentages (%).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of Lymphocytes per Leukocytes
Mean Change From Baseline in Lymphocytes/Leukocytes
% of Lymphocytes per LeukocytesSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-1.88 ± 9.010.19 ± 6.551.18 ± 6.092.61 ± 6.11
Week 4-0.88 ± 7.09-1.02 ± 6.34-1.18 ± 9.930.97 ± 8.00
Week 8-1.98 ± 10.59-1.40 ± 7.130.56 ± 10.201.97 ± 8.51
Week 120.21 ± 7.870.56 ± 10.58-0.44 ± 9.902.46 ± 10.18
Week 16-0.91 ± 8.33-1.49 ± 7.50-1.18 ± 9.650.12 ± 9.34
Week 20-1.97 ± 10.37-0.66 ± 6.580.88 ± 10.690.71 ± 10.32
Week 24-0.75 ± 8.69-0.56 ± 7.35-0.52 ± 10.551.85 ± 9.67
Week 28-1.18 ± 8.27-0.05 ± 8.51-0.05 ± 9.971.61 ± 10.55
Week 32-1.59 ± 7.69-2.56 ± 6.51-0.16 ± 7.700.70 ± 8.74
Week 40-2.60 ± 9.18-2.02 ± 5.99-1.36 ± 10.120.33 ± 8.41
Week 48-1.46 ± 11.29-3.71 ± 7.41-0.84 ± 9.421.69 ± 10.05
SecondaryMean Change From Baseline in Monocytes

Monocytes was measured in number of monocytes per liter (10\^9/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^9 monocytes per liter
Mean Change From Baseline in Monocytes
10^9 monocytes per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.01 ± 0.170.01 ± 0.180.05 ± 0.140.01 ± 0.13
Week 40.01 ± 0.180.04 ± 0.180.01 ± 0.140.06 ± 0.19
Week 8-0.03 ± 0.180.04 ± 0.180.03 ± 0.160.02 ± 0.17
Week 12-0.01 ± 0.190.00 ± 0.140.04 ± 0.180.06 ± 0.15
Week 16-0.01 ± 0.170.01 ± 0.170.05 ± 0.180.03 ± 0.14
Week 20-0.03 ± 0.190.00 ± 0.160.00 ± 0.130.05 ± 0.19
Week 240.00 ± 0.190.04 ± 0.190.03 ± 0.170.00 ± 0.17
Week 280.00 ± 0.200.04 ± 0.210.08 ± 0.190.02 ± 0.17
Week 32-0.01 ± 0.180.02 ± 0.190.05 ± 0.23-0.01 ± 0.19
Week 400.03 ± 0.170.05 ± 0.160.04 ± 0.16-0.01 ± 0.18
Week 48-0.02 ± 0.20-0.01 ± 0.130.03 ± 0.15-0.02 ± 0.18
SecondaryMean Change From Baseline in Monocytes/Leukocytes

Monocytes/Leukocytes was measured in percentages (%).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of Monocytes per Leukocytes
Mean Change From Baseline in Monocytes/Leukocytes
% of Monocytes per LeukocytesSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.87 ± 2.50-0.07 ± 2.460.23 ± 3.03-0.37 ± 2.25
Week 40.26 ± 3.300.27 ± 2.41-0.16 ± 3.11-0.24 ± 2.82
Week 8-0.21 ± 3.470.07 ± 3.610.51 ± 3.830.08 ± 3.12
Week 120.07 ± 2.79-0.11 ± 2.380.22 ± 3.370.45 ± 2.74
Week 160.06 ± 3.300.59 ± 2.850.43 ± 3.310.28 ± 3.13
Week 20-0.27 ± 3.840.56 ± 3.080.33 ± 3.810.43 ± 3.39
Week 240.06 ± 3.450.84 ± 2.970.46 ± 3.000.41 ± 3.24
Week 28-0.24 ± 3.540.69 ± 3.240.64 ± 3.670.94 ± 3.78
Week 32-0.08 ± 3.110.13 ± 2.620.46 ± 3.91-0.03 ± 3.76
Week 400.49 ± 3.550.64 ± 2.920.83 ± 3.690.59 ± 3.07
Week 48-0.04 ± 3.79-0.13 ± 2.410.47 ± 3.820.29 ± 3.30
SecondaryMean Change From Baseline in Neutrophils

Neutrophils was measured in number of neutrophils per liter (10\^9/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^9 neutrophils per liter
Mean Change From Baseline in Neutrophils
10^9 neutrophils per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.28 ± 2.430.26 ± 1.170.17 ± 1.33-0.01 ± 1.46
Week 40.07 ± 1.820.27 ± 1.400.21 ± 1.640.23 ± 1.96
Week 8-0.13 ± 2.200.41 ± 1.32-0.07 ± 1.53-0.20 ± 1.49
Week 12-0.24 ± 1.560.20 ± 1.650.10 ± 1.94-0.01 ± 2.03
Week 16-0.22 ± 2.130.20 ± 1.410.15 ± 1.61-0.20 ± 2.14
Week 20-0.07 ± 2.210.01 ± 1.22-0.39 ± 1.690.09 ± 2.51
Week 24-0.12 ± 2.24-0.06 ± 1.54-0.16 ± 1.77-0.38 ± 1.92
Week 280.04 ± 1.810.13 ± 1.640.10 ± 1.91-0.62 ± 1.78
Week 32-0.07 ± 1.870.33 ± 1.270.07 ± 1.54-0.40 ± 1.67
Week 400.16 ± 2.370.16 ± 1.31-0.32 ± 1.57-0.41 ± 1.88
Week 48-0.29 ± 1.580.55 ± 1.15-0.09 ± 2.02-0.54 ± 1.78
SecondaryMean Change From Baseline in Neutrophils/Leukocytes

Neutrophils/Leukocytes was measured in percentages (%).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of Neutrophils per Leukocytes
Mean Change From Baseline in Neutrophils/Leukocytes
% of Neutrophils per LeukocytesSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 22.99 ± 10.73-0.21 ± 7.94-1.20 ± 8.40-1.93 ± 8.18
Week 40.91 ± 9.370.89 ± 7.821.47 ± 12.70-0.37 ± 10.27
Week 82.15 ± 12.950.79 ± 8.80-1.17 ± 13.28-2.23 ± 10.92
Week 12-0.52 ± 9.44-1.25 ± 11.78-0.12 ± 13.18-2.90 ± 12.85
Week 160.77 ± 11.020.54 ± 8.500.56 ± 12.48-0.24 ± 12.23
Week 202.22 ± 13.21-0.73 ± 8.42-1.25 ± 14.29-0.71 ± 13.91
Week 240.65 ± 11.48-1.25 ± 8.740.10 ± 13.20-2.30 ± 12.41
Week 281.28 ± 10.38-0.88 ± 10.56-0.77 ± 13.27-2.60 ± 13.79
Week 321.67 ± 9.932.15 ± 7.42-0.47 ± 9.80-0.48 ± 12.08
Week 402.29 ± 11.661.36 ± 6.950.07 ± 13.23-0.93 ± 11.50
Week 481.41 ± 13.584.09 ± 8.400.30 ± 12.47-2.28 ± 12.38
SecondaryMean Change From Baseline in Platelets

Platelets was measured in number of platelets per liter (10\^9/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · 10^9 platelets per liter
Mean Change From Baseline in Platelets
10^9 platelets per literSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 25.9 ± 33.210.0 ± 40.01.4 ± 47.5-1.0 ± 52.0
Week 4-5.2 ± 51.30.0 ± 32.44.9 ± 43.88.1 ± 42.6
Week 80.2 ± 45.3-0.3 ± 40.33.9 ± 52.0-6.4 ± 40.5
Week 12-4.3 ± 50.6-1.7 ± 38.8-2.7 ± 49.01.8 ± 49.4
Week 160.7 ± 57.7-0.7 ± 40.5-1.5 ± 66.7-2.3 ± 68.1
Week 209.2 ± 57.1-3.3 ± 43.00.5 ± 44.60.8 ± 64.4
Week 240.2 ± 60.2-5.2 ± 43.82.4 ± 68.61.7 ± 67.0
Week 283.6 ± 64.61.8 ± 52.6-5.8 ± 71.91.5 ± 64.4
Week 324.0 ± 71.8-1.9 ± 55.4-4.6 ± 57.59.9 ± 93.8
Week 4010.3 ± 74.914.2 ± 52.7-8.8 ± 63.2-1.5 ± 67.4
Week 487.1 ± 67.43.5 ± 58.2-9.5 ± 70.9-8.8 ± 66.5
SecondaryMean Change From Baseline in Cluster of Differentiation 3 (CD3)

Cluster of differentiation 3 (CD3) was measured in cells per microliter (cells/µL).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · cells/µL
Mean Change From Baseline in Cluster of Differentiation 3 (CD3)
cells/µLSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 233.0 ± 313.677.7 ± 383.6106.6 ± 283.1126.9 ± 338.9
Week 4-30.6 ± 293.5-47.7 ± 504.324.0 ± 394.9227.2 ± 412.1
Week 8-64.7 ± 405.7-58.6 ± 422.8-20.5 ± 403.278.3 ± 560.0
Week 12-44.2 ± 283.2-48.8 ± 452.1-57.8 ± 385.143.7 ± 599.3
Week 16-81.9 ± 479.4-141.2 ± 516.1-4.5 ± 383.2-45.4 ± 520.8
Week 20-92.7 ± 391.1-173.4 ± 490.95.9 ± 352.9-89.9 ± 577.7
Week 24-85.8 ± 472.5-128.9 ± 569.4-88.5 ± 462.1-78.3 ± 570.7
Week 28-27.6 ± 507.3-81.2 ± 652.746.1 ± 482.27.4 ± 561.2
Week 32-70.9 ± 428.4-173.6 ± 565.818.0 ± 415.0-90.5 ± 504.0
Week 40-110.5 ± 526.4-166.9 ± 542.2-1.8 ± 410.731.7 ± 528.8
Week 48-115.6 ± 581.1-253.1 ± 637.036.1 ± 492.322.3 ± 558.0
SecondaryMean Change From Baseline in CD3/Lymphocytes

CD3/Lymphocytes was measured in percentages (%).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of CD3 per Leukocytes
Mean Change From Baseline in CD3/Lymphocytes
% of CD3 per LeukocytesSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.7 ± 6.1-0.9 ± 4.6-2.0 ± 5.7-0.2 ± 7.8
Week 4-2.1 ± 7.3-0.5 ± 6.0-1.9 ± 5.0-0.5 ± 6.8
Week 8-0.9 ± 6.1-1.2 ± 4.8-2.6 ± 5.90.6 ± 9.5
Week 12-0.4 ± 5.6-1.1 ± 8.2-2.4 ± 6.0-0.1 ± 9.2
Week 16-1.9 ± 5.8-1.6 ± 7.8-1.9 ± 7.6-1.4 ± 7.9
Week 20-0.8 ± 5.00.0 ± 8.6-2.3 ± 6.90.6 ± 9.2
Week 240.0 ± 6.5-0.1 ± 8.8-1.8 ± 6.618.7 ± 114.3
Week 28-0.2 ± 6.90.2 ± 8.3-2.9 ± 7.20.9 ± 10.2
Week 32-1.3 ± 7.00.2 ± 7.9-1.8 ± 6.81.4 ± 8.5
Week 400.2 ± 6.71.4 ± 6.90.5 ± 6.53.3 ± 7.9
Week 481.3 ± 8.00.3 ± 7.60.1 ± 6.24.5 ± 7.3
SecondaryMean Change From Baseline in Cluster of Differentiation 19 (CD19)

Cluster of differentiation 19 (CD19) was measured in cells per microliter (cells/µL).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · cells/µL
Mean Change From Baseline in Cluster of Differentiation 19 (CD19)
cells/µLSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 29.6 ± 56.712.3 ± 76.224.8 ± 71.063.4 ± 133.5
Week 4-2.8 ± 46.3-31.2 ± 177.09.2 ± 60.582.8 ± 154.5
Week 8-13.3 ± 72.9-29.4 ± 183.58.7 ± 70.819.4 ± 146.4
Week 12-2.6 ± 83.4-48.1 ± 207.1-17.9 ± 77.853.2 ± 203.6
Week 16-12.5 ± 84.3-50.1 ± 201.5-10.0 ± 92.413.2 ± 147.8
Week 20-15.1 ± 86.0-75.4 ± 216.6-2.5 ± 57.12.7 ± 132.6
Week 24-15.0 ± 89.3-77.2 ± 231.9-20.3 ± 72.0-1.1 ± 135.0
Week 28-20.6 ± 106.7-69.6 ± 206.7-13.1 ± 84.5-13.0 ± 123.2
Week 32-14.3 ± 106.3-75.8 ± 225.7-10.4 ± 93.0-20.9 ± 168.1
Week 40-24.8 ± 103.3-68.6 ± 211.0-26.9 ± 83.0-46.9 ± 138.0
Week 48-37.0 ± 132.7-82.4 ± 243.7-15.5 ± 83.2-41.2 ± 120.0
SecondaryMean Change From Baseline in CD19/Lymphocytes

CD19/Lymphocytes was measured in percentages (%).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of CD19 per Leukocytes
Mean Change From Baseline in CD19/Lymphocytes
% of CD19 per LeukocytesSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.3 ± 2.1-0.1 ± 3.01.0 ± 3.51.5 ± 5.9
Week 40.0 ± 2.9-0.5 ± 3.70.7 ± 3.32.8 ± 5.7
Week 80.1 ± 2.8-0.5 ± 4.20.7 ± 2.50.4 ± 6.4
Week 12-0.2 ± 3.2-1.0 ± 3.9-0.4 ± 3.11.7 ± 7.9
Week 160.0 ± 4.7-1.2 ± 5.0-0.4 ± 3.30.7 ± 5.9
Week 20-0.4 ± 3.8-2.1 ± 6.2-0.3 ± 3.0-0.2 ± 6.9
Week 24-0.9 ± 4.5-2.0 ± 6.5-0.6 ± 3.3-0.3 ± 7.3
Week 28-1.2 ± 5.4-2.5 ± 5.9-1.1 ± 3.3-1.0 ± 6.6
Week 32-0.4 ± 4.7-2.4 ± 5.5-0.6 ± 4.4-1.6 ± 6.3
Week 40-1.2 ± 4.7-2.6 ± 5.4-1.9 ± 4.2-3.4 ± 6.7
Week 48-1.2 ± 6.8-2.6 ± 7.2-1.6 ± 4.9-3.3 ± 6.2
SecondaryMean Change From Baseline in Aspartate Aminotransferase

Aspartate Aminotransferase was measured in units per liter (U/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · U/L
Mean Change From Baseline in Aspartate Aminotransferase
U/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.5 ± 8.80.2 ± 8.04.3 ± 43.10.0 ± 7.2
Week 4-0.1 ± 11.20.2 ± 7.4-1.1 ± 7.6-1.9 ± 8.0
Week 8-0.1 ± 8.7-1.5 ± 6.20.5 ± 13.0-1.1 ± 8.1
Week 125.1 ± 27.00.9 ± 6.2-1.8 ± 10.0-2.9 ± 7.1
Week 160.4 ± 7.70.0 ± 6.3-2.3 ± 11.6-2.8 ± 8.4
Week 204.1 ± 24.11.0 ± 11.5-0.7 ± 13.8-3.8 ± 8.1
Week 240.6 ± 11.81.6 ± 10.4-1.8 ± 11.5-3.8 ± 8.4
Week 280.0 ± 12.30.0 ± 10.2-1.5 ± 11.1-3.4 ± 9.1
Week 32-0.3 ± 11.00.3 ± 6.8-0.7 ± 12.9-3.4 ± 9.2
Week 40-0.6 ± 10.20.1 ± 9.1-0.3 ± 11.5-1.5 ± 9.8
Week 481.1 ± 10.80.1 ± 13.11.4 ± 13.4-2.1 ± 8.6
SecondaryMean Change From Baseline in Alanine Aminotransferase

Alanine Aminotransferase was measured in units per liter (U/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · U/L
Mean Change From Baseline in Alanine Aminotransferase
U/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 22.4 ± 14.12.6 ± 10.60.5 ± 11.1-0.1 ± 8.6
Week 40.8 ± 9.9-0.5 ± 8.50.9 ± 7.40.3 ± 8.2
Week 80.2 ± 10.2-0.8 ± 8.35.3 ± 28.8-0.6 ± 9.6
Week 127.0 ± 21.30.8 ± 14.3-0.8 ± 8.1-0.1 ± 7.6
Week 161.5 ± 13.3-0.4 ± 9.30.0 ± 10.3-1.1 ± 7.8
Week 205.3 ± 23.6-0.2 ± 10.21.4 ± 10.8-3.7 ± 6.3
Week 243.1 ± 20.90.5 ± 14.12.0 ± 12.0-2.8 ± 7.7
Week 281.0 ± 13.90.7 ± 10.5-0.4 ± 9.3-2.7 ± 7.2
Week 321.2 ± 13.4-0.5 ± 10.31.3 ± 10.8-3.2 ± 6.1
Week 40-0.5 ± 13.42.6 ± 12.83.0 ± 12.9-0.7 ± 8.3
Week 480.4 ± 11.5-1.2 ± 10.43.5 ± 17.0-1.1 ± 7.8
SecondaryMean Change From Baseline in Alkaline Phosphatase

Alkaline Phosphatase was measured in units per liter (U/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · U/L
Mean Change From Baseline in Alkaline Phosphatase
U/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 21.8 ± 10.72.4 ± 10.61.5 ± 8.0-3.6 ± 10.1
Week 4-1.7 ± 9.70.7 ± 9.2-0.7 ± 8.4-4.7 ± 9.4
Week 81.7 ± 12.92.4 ± 12.71.8 ± 15.6-6.1 ± 11.0
Week 122.2 ± 11.64.2 ± 16.41.9 ± 12.9-4.4 ± 11.8
Week 163.1 ± 10.72.7 ± 13.00.0 ± 10.4-6.7 ± 12.8
Week 203.9 ± 14.01.4 ± 11.81.4 ± 11.8-7.4 ± 11.2
Week 244.7 ± 15.03.7 ± 14.02.8 ± 11.6-2.7 ± 14.0
Week 282.8 ± 14.03.1 ± 14.21.9 ± 9.5-2.1 ± 13.5
Week 323.8 ± 14.62.7 ± 16.03.2 ± 12.11.0 ± 15.9
Week 402.4 ± 17.11.3 ± 13.12.7 ± 13.0-3.0 ± 18.0
Week 482.6 ± 13.34.0 ± 16.85.5 ± 12.8-4.5 ± 18.8
SecondaryMean Change From Baseline in Gamma Glutamyl Transferase

Gamma Glutamyl Transferase was measured in units per liter (U/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · U/L
Mean Change From Baseline in Gamma Glutamyl Transferase
U/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.3 ± 7.62.0 ± 11.58.8 ± 68.9-3.4 ± 24.3
Week 42.1 ± 8.7-1.3 ± 8.82.7 ± 28.5-6.5 ± 35.5
Week 83.5 ± 23.00.3 ± 10.5-2.8 ± 49.3-9.2 ± 43.3
Week 124.1 ± 21.00.5 ± 13.4-5.1 ± 29.3-8.3 ± 46.1
Week 166.5 ± 20.22.1 ± 12.5-6.1 ± 45.0-10.6 ± 47.7
Week 203.5 ± 14.10.2 ± 13.4-3.7 ± 50.3-8.5 ± 50.5
Week 247.1 ± 22.04.0 ± 18.7-0.4 ± 53.1-9.5 ± 47.2
Week 284.6 ± 25.72.2 ± 18.3-7.0 ± 46.80.0 ± 23.1
Week 324.4 ± 28.61.5 ± 16.7-5.9 ± 44.5-8.2 ± 37.4
Week 403.4 ± 41.35.7 ± 32.40.4 ± 10.1-9.1 ± 45.3
Week 481.8 ± 11.45.3 ± 23.94.7 ± 21.6-9.8 ± 44.5
SecondaryMean Change From Baseline in Bilirubin

Bilirubin was measured in micromols per liter (µmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · μmol/L
Mean Change From Baseline in Bilirubin
μmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.35 ± 2.72-0.48 ± 2.710.28 ± 2.38-0.78 ± 3.13
Week 40.07 ± 2.50-0.18 ± 2.09-0.05 ± 2.14-0.79 ± 2.80
Week 8-0.09 ± 2.66-0.69 ± 2.22-0.19 ± 2.13-0.23 ± 2.80
Week 12-0.04 ± 2.60-0.70 ± 2.740.37 ± 2.17-0.33 ± 3.28
Week 160.06 ± 2.41-0.45 ± 2.43-0.20 ± 2.71-0.51 ± 3.64
Week 20-0.54 ± 2.89-0.38 ± 2.510.51 ± 2.81-0.30 ± 3.03
Week 240.08 ± 2.75-0.14 ± 2.860.54 ± 2.18-0.38 ± 3.57
Week 28-0.10 ± 2.98-0.26 ± 3.230.79 ± 2.71-0.82 ± 2.61
Week 320.09 ± 2.75-0.38 ± 2.610.93 ± 3.18-0.38 ± 3.61
Week 40-0.26 ± 3.700.07 ± 3.181.03 ± 2.35-0.15 ± 2.64
Week 480.69 ± 3.57-0.50 ± 3.120.79 ± 3.04-0.20 ± 2.52
SecondaryMean Change From Baseline in Direct Bilirubin

Direct Bilirubin was measured in micromols per liter (µmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · μmol/L
Mean Change From Baseline in Direct Bilirubin
μmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.03 ± 0.92-0.06 ± 0.920.09 ± 1.12-0.24 ± 1.10
Week 40.10 ± 1.030.03 ± 0.75-0.04 ± 0.82-0.10 ± 0.93
Week 80.03 ± 0.91-0.18 ± 0.55-0.17 ± 0.860.03 ± 1.10
Week 120.15 ± 0.99-0.07 ± 0.95-0.01 ± 1.06-0.05 ± 1.30
Week 160.18 ± 0.81-0.01 ± 0.66-0.07 ± 1.04-0.01 ± 1.40
Week 20-0.04 ± 0.950.07 ± 0.910.02 ± 0.940.00 ± 1.19
Week 240.05 ± 1.100.14 ± 0.950.08 ± 1.02-0.08 ± 1.25
Week 280.06 ± 1.06-0.06 ± 1.000.11 ± 0.80-0.06 ± 1.15
Week 320.12 ± 1.160.05 ± 0.900.21 ± 1.21-0.04 ± 1.36
Week 400.07 ± 1.310.03 ± 0.760.23 ± 1.000.07 ± 1.05
Week 480.31 ± 1.34-0.05 ± 1.010.20 ± 1.250.08 ± 0.98
SecondaryMean Change From Baseline in Lactate Dehydrogenase

Lactate Dehydrogenase was measured in units per liter (U/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · U/L
Mean Change From Baseline in Lactate Dehydrogenase
U/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-3.3 ± 27.8-7.8 ± 21.2-5.9 ± 35.2-12.8 ± 24.8
Week 4-3.0 ± 23.4-3.7 ± 37.0-5.6 ± 35.6-18.5 ± 34.1
Week 8-5.7 ± 27.4-11.8 ± 31.5-9.2 ± 39.0-20.4 ± 37.4
Week 123.0 ± 28.7-7.4 ± 34.6-11.1 ± 45.1-24.4 ± 39.0
Week 16-2.2 ± 25.5-11.1 ± 29.9-10.6 ± 48.6-22.4 ± 43.3
Week 20-0.7 ± 33.9-10.8 ± 37.0-9.9 ± 47.8-28.5 ± 32.1
Week 24-4.5 ± 31.3-14.3 ± 31.5-14.6 ± 34.4-29.3 ± 32.2
Week 280.0 ± 40.8-16.0 ± 40.9-13.2 ± 35.0-34.8 ± 36.9
Week 325.0 ± 55.0-9.9 ± 43.4-8.1 ± 33.5-22.9 ± 40.6
Week 40-1.6 ± 38.1-2.9 ± 41.1-8.0 ± 28.4-20.5 ± 40.1
Week 48-8.8 ± 35.2-4.2 ± 54.3-1.5 ± 32.7-16.0 ± 36.3
SecondaryMean Change From Baseline in Creatinine

Creatinine was measured in micromols per liter (µmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · μmol/L
Mean Change From Baseline in Creatinine
μmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.9 ± 9.1-0.1 ± 8.01.5 ± 5.80.6 ± 7.2
Week 4-0.8 ± 8.9-0.2 ± 9.3-0.6 ± 7.3-1.4 ± 8.2
Week 80.5 ± 7.00.3 ± 7.6-0.5 ± 6.90.1 ± 8.4
Week 12-0.3 ± 7.01.4 ± 7.5-0.4 ± 6.4-0.7 ± 8.2
Week 16-0.1 ± 9.81.0 ± 8.20.7 ± 6.8-1.1 ± 9.4
Week 200.7 ± 8.61.4 ± 10.20.8 ± 6.9-0.3 ± 7.7
Week 240.0 ± 8.80.8 ± 8.80.3 ± 6.60.9 ± 9.7
Week 282.5 ± 10.02.7 ± 10.01.0 ± 7.8-0.9 ± 7.8
Week 325.5 ± 35.70.5 ± 8.13.6 ± 7.81.6 ± 11.2
Week 402.3 ± 9.52.2 ± 8.53.9 ± 6.03.0 ± 8.4
Week 481.9 ± 10.60.7 ± 7.62.5 ± 5.22.9 ± 9.8
SecondaryMean Change From Baseline in Urea Nitrogen

Urea Nitrogen was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Urea Nitrogen
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.28 ± 1.55-0.09 ± 1.23-0.05 ± 1.32-0.02 ± 1.31
Week 4-0.07 ± 1.21-0.33 ± 1.52-0.14 ± 1.200.04 ± 1.19
Week 80.06 ± 1.25-0.26 ± 1.22-0.19 ± 1.070.17 ± 1.59
Week 120.03 ± 1.13-0.39 ± 1.31-0.29 ± 1.17-0.22 ± 1.15
Week 160.19 ± 1.35-0.18 ± 1.400.19 ± 1.49-0.03 ± 1.41
Week 20-0.18 ± 1.29-0.20 ± 1.33-0.25 ± 1.22-0.16 ± 1.08
Week 240.08 ± 1.69-0.44 ± 1.38-0.13 ± 1.18-0.09 ± 1.50
Week 280.13 ± 1.380.03 ± 1.61-0.23 ± 1.26-0.22 ± 1.14
Week 320.40 ± 2.37-0.30 ± 1.650.21 ± 1.170.10 ± 1.43
Week 400.29 ± 1.540.10 ± 1.730.21 ± 1.200.14 ± 1.43
Week 480.05 ± 1.22-0.31 ± 1.540.23 ± 1.38-0.02 ± 1.56
SecondaryMean Change From Baseline in Sodium

Sodium was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Sodium
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.1 ± 1.9-0.4 ± 2.40.1 ± 1.60.0 ± 2.2
Week 4-0.3 ± 2.0-0.6 ± 2.10.3 ± 2.1-0.1 ± 2.4
Week 80.1 ± 2.2-0.4 ± 2.40.3 ± 2.20.1 ± 2.3
Week 12-0.3 ± 2.0-0.5 ± 2.00.2 ± 2.00.1 ± 2.3
Week 16-0.4 ± 2.3-0.2 ± 1.90.0 ± 2.0-0.2 ± 2.3
Week 200.3 ± 2.2-0.8 ± 2.2-0.1 ± 2.0-0.5 ± 2.4
Week 24-0.1 ± 2.5-0.4 ± 2.20.0 ± 2.2-0.3 ± 2.1
Week 280.0 ± 1.9-0.4 ± 2.40.2 ± 1.90.1 ± 2.3
Week 320.0 ± 2.3-0.8 ± 3.20.1 ± 2.10.2 ± 2.2
Week 40-0.1 ± 2.2-1.2 ± 2.2-0.1 ± 1.6-0.3 ± 2.4
Week 48-0.4 ± 2.0-1.1 ± 2.6-0.5 ± 1.70.2 ± 2.3
SecondaryMean Change From Baseline in Potassium

Potassium was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Potassium
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.04 ± 0.450.15 ± 0.400.00 ± 0.36-0.03 ± 0.37
Week 40.06 ± 0.440.08 ± 0.35-0.07 ± 0.41-0.12 ± 0.40
Week 8-0.04 ± 0.400.11 ± 0.380.00 ± 0.35-0.07 ± 0.40
Week 12-0.01 ± 0.330.02 ± 0.31-0.07 ± 0.41-0.12 ± 0.34
Week 16-0.01 ± 0.340.16 ± 0.33-0.09 ± 0.42-0.05 ± 0.33
Week 200.04 ± 0.380.14 ± 0.33-0.04 ± 0.46-0.08 ± 0.37
Week 240.06 ± 0.430.07 ± 0.390.03 ± 0.33-0.11 ± 0.37
Week 280.09 ± 0.430.12 ± 0.470.06 ± 0.420.03 ± 0.45
Week 320.03 ± 0.440.07 ± 0.440.10 ± 0.46-0.05 ± 0.38
Week 400.06 ± 0.330.16 ± 0.510.16 ± 0.39-0.06 ± 0.37
Week 48-0.01 ± 0.300.00 ± 0.30-0.02 ± 0.39-0.07 ± 0.40
SecondaryMean Change From Baseline in Calcium

Calcium was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Calcium
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.008 ± 0.104-0.001 ± 0.1030.004 ± 0.088-0.008 ± 0.092
Week 40.007 ± 0.108-0.018 ± 0.099-0.018 ± 0.090-0.001 ± 0.086
Week 8-0.006 ± 0.093-0.033 ± 0.117-0.014 ± 0.106-0.003 ± 0.089
Week 120.006 ± 0.108-0.011 ± 0.121-0.013 ± 0.097-0.004 ± 0.111
Week 16-0.025 ± 0.106-0.004 ± 0.088-0.013 ± 0.095-0.024 ± 0.119
Week 20-0.036 ± 0.116-0.020 ± 0.084-0.015 ± 0.1080.005 ± 0.080
Week 24-0.027 ± 0.106-0.026 ± 0.094-0.012 ± 0.0950.007 ± 0.100
Week 28-0.031 ± 0.121-0.039 ± 0.091-0.016 ± 0.113-0.014 ± 0.092
Week 320.003 ± 0.098-0.043 ± 0.0990.019 ± 0.107-0.001 ± 0.105
Week 40-0.027 ± 0.114-0.022 ± 0.1150.006 ± 0.115-0.012 ± 0.105
Week 48-0.013 ± 0.096-0.037 ± 0.119-0.004 ± 0.104-0.017 ± 0.110
SecondaryMean Change From Baseline in Phosphate

Phosphate was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Phosphate
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.044 ± 0.1630.032 ± 0.192-0.047 ± 0.2300.033 ± 0.168
Week 4-0.004 ± 0.162-0.029 ± 0.185-0.070 ± 0.1870.020 ± 0.163
Week 80.006 ± 0.178-0.063 ± 0.225-0.028 ± 0.2070.051 ± 0.187
Week 120.029 ± 0.159-0.004 ± 0.149-0.015 ± 0.2360.045 ± 0.183
Week 16-0.010 ± 0.1860.012 ± 0.182-0.025 ± 0.1950.005 ± 0.178
Week 20-0.030 ± 0.208-0.037 ± 0.244-0.031 ± 0.1770.013 ± 0.187
Week 24-0.013 ± 0.181-0.042 ± 0.160-0.040 ± 0.2290.035 ± 0.200
Week 28-0.024 ± 0.1890.008 ± 0.238-0.031 ± 0.2320.037 ± 0.184
Week 32-0.002 ± 0.217-0.056 ± 0.2230.015 ± 0.2200.030 ± 0.190
Week 400.018 ± 0.2070.009 ± 0.196-0.022 ± 0.2080.034 ± 0.224
Week 480.032 ± 0.183-0.012 ± 0.167-0.044 ± 0.2140.035 ± 0.190
SecondaryMean Change From Baseline in Cholesterol

Cholesterol was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Cholesterol
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.00 ± 0.49-0.07 ± 0.46-0.06 ± 0.51-0.19 ± 0.47
Week 4-0.08 ± 0.49-0.03 ± 0.46-0.07 ± 0.68-0.07 ± 0.57
Week 8-0.09 ± 0.57-0.07 ± 0.46-0.15 ± 0.81-0.17 ± 0.59
Week 12-0.14 ± 0.72-0.16 ± 0.61-0.23 ± 0.68-0.10 ± 0.75
Week 16-0.16 ± 0.80-0.16 ± 0.66-0.35 ± 0.80-0.27 ± 0.72
Week 20-0.27 ± 0.77-0.22 ± 0.60-0.42 ± 0.81-0.23 ± 0.85
Week 24-0.12 ± 0.87-0.17 ± 0.66-0.28 ± 0.96-0.16 ± 0.78
Week 28-0.17 ± 0.89-0.37 ± 0.63-0.35 ± 0.97-0.29 ± 0.80
Week 32-0.13 ± 0.86-0.22 ± 0.63-0.16 ± 0.83-0.15 ± 0.81
Week 40-0.34 ± 0.87-0.25 ± 0.80-0.19 ± 0.77-0.13 ± 1.15
Week 48-0.40 ± 0.80-0.36 ± 0.74-0.23 ± 0.97-0.18 ± 1.09
SecondaryMean Change From Baseline in Triglycerides

Triglycerides was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Triglycerides
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.176 ± 1.5930.046 ± 0.6830.110 ± 0.8550.183 ± 0.751
Week 4-0.189 ± 1.212-0.004 ± 0.510-0.030 ± 0.4710.084 ± 0.529
Week 8-0.182 ± 1.5540.076 ± 0.582-0.084 ± 0.4980.046 ± 0.585
Week 12-0.265 ± 1.4450.088 ± 0.7130.063 ± 0.5780.009 ± 0.514
Week 16-0.164 ± 1.3450.099 ± 1.4880.142 ± 0.5800.112 ± 1.035
Week 20-0.233 ± 1.391-0.104 ± 0.8370.008 ± 0.622-0.060 ± 0.707
Week 24-0.263 ± 1.515-0.045 ± 0.774-0.013 ± 0.608-0.030 ± 0.707
Week 28-0.013 ± 1.559-0.125 ± 0.782-0.043 ± 0.423-0.036 ± 0.663
Week 32-0.260 ± 1.4180.045 ± 0.7170.057 ± 0.5320.112 ± 0.718
Week 40-0.134 ± 1.175-0.159 ± 0.7650.177 ± 0.8210.022 ± 0.644
Week 48-0.242 ± 1.516-0.149 ± 0.7580.114 ± 0.5070.054 ± 0.752
SecondaryMean Change From Baseline in Protein

Protein was measured in grams per liter (g/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · g/L
Mean Change From Baseline in Protein
g/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.2 ± 3.7-1.2 ± 4.0-1.0 ± 4.2-1.1 ± 3.8
Week 4-1.5 ± 4.4-1.6 ± 4.2-1.5 ± 4.7-1.7 ± 4.4
Week 8-1.1 ± 4.4-2.1 ± 4.1-1.8 ± 5.7-2.0 ± 3.9
Week 12-0.8 ± 3.8-1.3 ± 4.7-1.4 ± 5.2-1.2 ± 5.8
Week 16-1.2 ± 5.2-0.3 ± 4.1-2.3 ± 5.6-3.8 ± 5.0
Week 20-2.7 ± 6.0-1.6 ± 4.6-2.6 ± 4.7-3.1 ± 5.4
Week 24-2.2 ± 7.5-1.8 ± 4.6-1.8 ± 5.5-2.0 ± 4.7
Week 28-3.1 ± 7.4-2.4 ± 4.6-2.5 ± 5.7-3.6 ± 6.4
Week 32-1.4 ± 6.9-1.5 ± 5.7-0.8 ± 5.0-1.9 ± 6.4
Week 40-2.2 ± 6.5-0.9 ± 5.0-1.8 ± 5.3-2.6 ± 6.1
Week 48-2.3 ± 6.2-2.4 ± 5.9-0.9 ± 5.1-3.4 ± 6.4
SecondaryMean Change From Baseline in Albumin

Albumin was measured in grams per liter (g/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · g/L
Mean Change From Baseline in Albumin
g/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.1 ± 2.1-0.4 ± 2.4-0.5 ± 2.4-0.5 ± 1.9
Week 4-0.5 ± 2.4-0.4 ± 2.3-0.2 ± 2.4-0.3 ± 1.9
Week 8-0.3 ± 2.3-0.3 ± 2.5-0.3 ± 3.00.1 ± 2.2
Week 12-0.1 ± 2.20.2 ± 2.70.2 ± 2.70.7 ± 3.0
Week 160.0 ± 2.51.0 ± 2.50.1 ± 2.9-0.2 ± 2.9
Week 20-0.7 ± 2.70.1 ± 2.70.4 ± 2.40.4 ± 2.2
Week 24-0.1 ± 2.90.0 ± 2.10.4 ± 2.41.2 ± 2.7
Week 28-0.7 ± 3.0-0.4 ± 2.30.1 ± 2.90.1 ± 2.6
Week 320.6 ± 2.8-0.1 ± 3.00.9 ± 3.20.7 ± 2.8
Week 400.1 ± 2.8-0.1 ± 2.90.2 ± 2.60.3 ± 3.0
Week 480.1 ± 2.8-0.7 ± 3.00.2 ± 3.0-0.8 ± 3.5
SecondaryMean Change From Baseline in Glucose

Glucose was measured in millimoles per liter (mmol/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · mmol/L
Mean Change From Baseline in Glucose
mmol/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 20.18 ± 0.750.26 ± 0.700.09 ± 0.780.13 ± 1.28
Week 40.04 ± 0.710.03 ± 0.70-0.04 ± 0.900.11 ± 1.10
Week 80.17 ± 0.660.12 ± 0.900.23 ± 0.950.12 ± 1.16
Week 12-0.08 ± 0.690.08 ± 0.66-0.13 ± 0.79-0.15 ± 0.99
Week 160.11 ± 0.770.06 ± 0.630.16 ± 0.92-0.18 ± 1.47
Week 200.16 ± 0.850.20 ± 0.840.13 ± 0.83-0.08 ± 1.01
Week 24-0.07 ± 0.850.05 ± 0.49-0.09 ± 0.73-0.22 ± 1.06
Week 280.22 ± 1.010.09 ± 0.76-0.01 ± 0.740.07 ± 1.22
Week 32-0.04 ± 0.72-0.07 ± 0.63-0.08 ± 0.650.06 ± 1.10
Week 40-0.05 ± 0.620.08 ± 0.71-0.09 ± 0.68-0.08 ± 1.07
Week 48-0.14 ± 0.78-0.11 ± 0.61-0.06 ± 0.64-0.14 ± 1.25
SecondaryMean Change From Baseline in Lipase, Pancreatic

Lipase, Pancreatic was measured in units per liter (U/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · U/L
Mean Change From Baseline in Lipase, Pancreatic
U/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-1.1 ± 10.52.2 ± 11.90.1 ± 9.2-0.2 ± 7.5
Week 4-2.1 ± 9.80.9 ± 9.10.1 ± 10.6-1.2 ± 10.0
Week 8-3.1 ± 9.23.7 ± 11.82.0 ± 20.0-1.8 ± 10.3
Week 12-0.5 ± 8.71.0 ± 11.1-0.7 ± 13.4-0.6 ± 9.6
Week 160.4 ± 7.42.7 ± 8.40.5 ± 11.3-0.2 ± 11.8
Week 20-0.6 ± 10.42.1 ± 8.0-0.9 ± 9.0-1.7 ± 9.3
Week 24-0.5 ± 11.0-0.1 ± 9.1-0.1 ± 8.11.2 ± 11.8
Week 281.6 ± 13.11.7 ± 10.50.5 ± 11.91.7 ± 14.1
Week 321.1 ± 15.11.0 ± 11.01.2 ± 10.63.8 ± 21.6
Week 401.2 ± 11.01.3 ± 7.0-0.3 ± 8.92.5 ± 8.9
Week 481.4 ± 10.12.2 ± 10.00.3 ± 10.73.7 ± 10.2
SecondaryMean Change From Baseline in Creatine Kinase

Creatine Kinase was measured in units per liter (U/L).

Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · U/L
Mean Change From Baseline in Creatine Kinase
U/LSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-3.0 ± 67.1-2.2 ± 55.6-2.2 ± 18.20.1 ± 46.5
Week 429.6 ± 218.4-6.2 ± 54.83.2 ± 22.0-16.9 ± 56.5
Week 8-4.9 ± 56.9-8.5 ± 52.7-1.5 ± 23.6-4.6 ± 122.1
Week 12-6.3 ± 57.5-8.4 ± 85.8-3.0 ± 22.4-29.4 ± 80.7
Week 160.9 ± 59.4-11.5 ± 105.1-7.5 ± 22.2-23.2 ± 106.3
Week 20-8.2 ± 60.05.9 ± 149.1-3.5 ± 22.2-33.4 ± 95.3
Week 24-6.4 ± 48.6-5.4 ± 123.7-2.6 ± 27.4-27.7 ± 98.9
Week 28-1.5 ± 67.3-19.1 ± 131.5-0.7 ± 25.4-36.7 ± 103.8
Week 322.0 ± 67.0-10.0 ± 167.034.0 ± 222.1-24.2 ± 91.2
Week 409.9 ± 109.1-20.4 ± 131.4-2.7 ± 25.4-16.3 ± 106.4
Week 487.8 ± 67.3-20.4 ± 138.3-3.6 ± 25.5-33.4 ± 106.5
SecondaryMean Change From Baseline in pH
Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · pH
Mean Change From Baseline in pH
pHSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.01 ± 0.660.03 ± 0.62-0.07 ± 0.670.15 ± 0.78
Week 40.10 ± 0.770.15 ± 0.520.06 ± 0.720.16 ± 0.74
Week 8-0.12 ± 0.790.00 ± 0.62-0.08 ± 0.56-0.04 ± 0.65
Week 120.00 ± 0.810.15 ± 0.690.03 ± 0.790.20 ± 0.83
Week 16-0.02 ± 0.610.00 ± 0.51-0.09 ± 0.810.11 ± 0.69
Week 20-0.11 ± 0.75-0.01 ± 0.590.06 ± 0.580.07 ± 0.88
Week 240.03 ± 0.85-0.01 ± 0.46-0.11 ± 0.810.02 ± 0.81
Week 28-0.13 ± 0.84-0.06 ± 0.57-0.05 ± 0.73-0.01 ± 0.69
Week 32-0.02 ± 0.75-0.03 ± 0.55-0.18 ± 0.660.09 ± 0.86
Week 40-0.14 ± 0.810.19 ± 0.66-0.21 ± 0.81-0.07 ± 0.62
Week 48-0.11 ± 0.660.06 ± 0.73-0.11 ± 0.74-0.08 ± 0.72
SecondaryMean Change From Baseline in Erythrocytes (/HPF)
Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of Erythrocytes per HPF
Mean Change From Baseline in Erythrocytes (/HPF)
% of Erythrocytes per HPFSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-6.8 ± 53.70.1 ± 8.40.2 ± 2.40.9 ± 7.9
Week 4-8.7 ± 52.6-0.8 ± 4.11.4 ± 10.5-0.6 ± 3.2
Week 8-8.7 ± 53.5-0.3 ± 6.90.4 ± 6.10.0 ± 6.8
Week 12-8.6 ± 52.61.3 ± 17.4-0.4 ± 2.417.4 ± 118.5
Week 16-5.7 ± 48.0-1.3 ± 4.1-0.6 ± 2.6-0.5 ± 5.5
Week 20-7.7 ± 53.7-1.0 ± 3.5-0.1 ± 3.9-0.6 ± 4.4
Week 24-7.2 ± 53.5-1.2 ± 3.9-0.3 ± 2.3-0.9 ± 4.6
Week 28-7.6 ± 51.3-1.3 ± 4.2-0.7 ± 2.93.0 ± 16.9
Week 32-8.5 ± 52.54.9 ± 41.80.0 ± 3.90.1 ± 4.5
Week 40-9.1 ± 53.23.5 ± 18.8-0.5 ± 3.50.4 ± 5.4
Week 48-9.7 ± 56.3-0.4 ± 5.41.9 ± 15.50.1 ± 4.0
SecondaryMean Change From Baseline in Leukocytes (/HPF)
Time frame:
From Baseline (Week 1) to Week 48
Reported as:
Mean · % of Leukocytes per HPF
Mean Change From Baseline in Leukocytes (/HPF)
% of Leukocytes per HPFSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Week 2-0.1 ± 11.4-1.4 ± 8.1-0.8 ± 2.92.9 ± 13.7
Week 4-0.2 ± 9.0-0.6 ± 8.5-0.7 ± 4.53.0 ± 12.6
Week 8-1.2 ± 10.44.8 ± 29.3-0.3 ± 6.83.0 ± 14.4
Week 12-1.1 ± 11.34.4 ± 42.2-1.3 ± 4.22.7 ± 13.9
Week 160.1 ± 9.6-1.6 ± 12.5-0.2 ± 9.61.8 ± 12.9
Week 20-0.1 ± 10.13.7 ± 13.30.4 ± 9.81.7 ± 4.0
Week 24-1.0 ± 10.910.7 ± 52.1-0.7 ± 4.50.4 ± 4.5
Week 28-0.2 ± 9.62.4 ± 9.7-1.1 ± 4.42.0 ± 10.1
Week 32-0.6 ± 10.8-0.5 ± 13.5-1.0 ± 5.44.1 ± 15.7
Week 40-1.6 ± 10.42.2 ± 19.81.4 ± 7.76.8 ± 30.9
Week 48-0.3 ± 8.910.8 ± 71.9-1.0 ± 4.00.8 ± 5.3

Adverse events

Collected over Adverse events were collected from Baseline (Week 1) until end of the study (Week 48). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOC + Placebo iv Q4W (SS)0/45 (0%)6/45 (13.3%)19/45 (42.2%)
SOC + DZP 6mg/kg iv Q4W (SS)0/45 (0%)5/45 (11.1%)23/45 (51.1%)
SOC + DZP 24mg/kg iv Q4W (SS)0/45 (0%)6/45 (13.3%)22/45 (48.9%)
SOC + DZP 45mg/kg iv Q4W (SS)0/47 (0%)5/47 (10.6%)21/47 (44.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders2/450/450/451/47
AnaemiaBlood and lymphatic system disorders0/450/451/450/47
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders0/451/450/450/47
CellulitisInfections and infestations1/450/451/450/47
Herpes zosterInfections and infestations1/451/450/450/47
InfluenzaInfections and infestations1/450/450/450/47
Pseudomonal bacteraemiaInfections and infestations0/450/451/450/47
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/451/450/450/47
Lupus nephritisRenal and urinary disorders0/451/450/451/47
PneumothoraxRespiratory, thoracic and mediastinal disorders0/450/451/450/47
Most frequent other events
Showing 10 of 14
Most frequent other events
EventSOC + Placebo iv Q4W (SS)SOC + DZP 6mg/kg iv Q4W (SS)SOC + DZP 24mg/kg iv Q4W (SS)SOC + DZP 45mg/kg iv Q4W (SS)
DyspepsiaGastrointestinal disorders5/451/450/450/47
NasopharyngitisInfections and infestations2/455/455/454/47
HeadacheNervous system disorders5/455/454/452/47
Upper respiratory tract infectionInfections and infestations4/454/453/455/47
DiarrhoeaGastrointestinal disorders2/454/453/453/47
PharyngitisInfections and infestations1/454/454/453/47
Urinary tract infectionInfections and infestations2/454/452/452/47
Back painMusculoskeletal and connective tissue disorders2/454/450/452/47
NauseaGastrointestinal disorders2/451/453/451/47
BronchitisInfections and infestations0/453/451/452/47

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all study participants who were randomized and received at least 1 dose (any amount) of study drug.

Age, Categorical
Age, Categorical(Participants)SOC + Placebo iv Q4WSOC + DZP 6mg/kg iv Q4WSOC + DZP 24mg/kg iv Q4WSOC + DZP 45mg/kg iv Q4WTotal Title
<=18 years00000
Between 18 and 65 years44444446178
>=65 years11114
Age, Continuous
Age, Continuous(years)SOC + Placebo iv Q4WSOC + DZP 6mg/kg iv Q4WSOC + DZP 24mg/kg iv Q4WSOC + DZP 45mg/kg iv Q4WTotal Title
Mean43.50 ± 12.7940.81 ± 11.5542.77 ± 10.4238.94 ± 12.9241.48 ± 12.01
Sex: Female, Male
Sex: Female, Male(Participants)SOC + Placebo iv Q4WSOC + DZP 6mg/kg iv Q4WSOC + DZP 24mg/kg iv Q4WSOC + DZP 45mg/kg iv Q4WTotal Title
Female41424043166
Male435416
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOC + Placebo iv Q4WSOC + DZP 6mg/kg iv Q4WSOC + DZP 24mg/kg iv Q4WSOC + DZP 45mg/kg iv Q4WTotal Title
American Indian or Alaska Native21115
Asian10102
Black141612
White27263327113
Other/Mixed141491350
08

Study locations

71 sites
  • Sl0023 312
    Birmingham, Alabama 35294, United States
  • Sl0023 307
    El Cajon, California 92020, United States
  • Sl0023 309
    El Cajon, California 92020, United States
  • Sl0023 323
    Huntington Beach, California 92646, United States
  • Sl0023 311
    Los Angeles, California 90048, United States
  • Sl0023 314
    Thousand Oaks, California 91360, United States
  • Sl0023 302
    Upland, California 91786, United States
  • Sl0023 326
    New Haven, Connecticut 06520, United States
  • Sl0023 304
    Clearwater, Florida 33765, United States
  • Sl0023 322
    DeBary, Florida 32713, United States
  • Sl0023 301
    Miami Lakes, Florida 33014, United States
  • Sl0023 321
    Miami, Florida 33136, United States
  • Sl0023 319
    Palm Harbor, Florida 34684, United States
  • Sl0023 310
    Tampa, Florida 33603, United States
  • Sl0023 324
    Atlanta, Georgia 30303, United States
  • Sl0023 327
    Stockbridge, Georgia 30281, United States
  • Sl0023 320
    Idaho Falls, Idaho 83404, United States
  • Sl0023 306
    Albuquerque, New Mexico 87104, United States
  • Sl0023 313
    Lake Success, New York 11042, United States
  • Sl0023 305
    Oklahoma City, Oklahoma 73101, United States
  • Sl0023 315
    Jackson, Tennessee 38305, United States
  • Sl0023 308
    Memphis, Tennessee 38119, United States
  • Sl0023 317
    Amarillo, Texas 79124, United States
  • Sl0023 303
    Houston, Texas 77034, United States
  • Sl0023 328
    Spokane, Washington 99204, United States
  • Sl0023 101
    Plovdiv, Bulgaria
  • Sl0023 102
    Plovdiv, Bulgaria
  • Sl0023 202
    Providencia, Chile
  • Sl0023 203
    Providencia, Chile
  • Sl0023 201
    Puerto Varas, Chile
  • Sl0023 204
    Vina del Mar, Chile
  • Sl0023 213
    Barranquilla, Colombia
  • Sl0023 212
    Bogotá, Colombia
  • Sl0023 214
    Bogotá, Colombia
  • Sl0023 216
    Bucaramanga, Colombia
  • Sl0023 211
    Chía, Colombia
  • Sl0023 215
    Medellín, Colombia
  • Sl0023 341
    Hannover, Germany
  • Sl0023 113
    Leipzig, Germany
  • Sl0023 124
    Debrecen, Hungary
  • Sl0023 225
    Guadalajara, Mexico
  • Sl0023 224
    León, Mexico
  • Sl0023 221
    Mexico, Mexico
  • Sl0023 222
    San Luis Potosí, Mexico
  • Sl0023 232
    Arequipa, Peru
  • Sl0023 231
    Lima, Peru
  • Sl0023 234
    Lima, Peru
  • Sl0023 235
    Lima, Peru
  • Sl0023 133
    Bytom, Poland
  • Sl0023 136
    Lublin, Poland
  • Sl0023 131
    Poznan, Poland
  • Sl0023 134
    Sosnowiec, Poland
  • Sl0023 135
    Warszawa, Poland
  • Sl0023 138
    Łódź, Poland
  • Sl0023 146
    Brasov, Romania
  • Sl0023 142
    Bucuresti, Romania
  • Sl0023 144
    Cluj-Napoca, Romania
  • Sl0023 141
    Galati, Romania
  • Sl0023 157
    Kazan, Russian Federation
  • Sl0023 156
    Kemerovo, Russian Federation
  • Sl0023 152
    Saint Petersburg, Russian Federation
  • Sl0023 155
    Voronezh, Russian Federation
  • Sl0023 151
    Yaroslavl', Russian Federation
  • Sl0023 153
    Yekaterinburg, Russian Federation
  • Sl0023 161
    Barcelona, Spain
  • Sl0023 162
    Madrid, Spain
  • Sl0023 166
    Tenerife, Spain
  • Sl0023 172
    Kyiv, Ukraine
  • Sl0023 175
    Kyiv, Ukraine
  • Sl0023 171
    Odessa, Ukraine
  • Sl0023 173
    Vinnytsya, Ukraine
09

References and documents

Publications

  • Morel T, Cano S, Bartlett SJ, Gordon C, Haier B, Regnault A, Schneider M, Stach C, Cleanthous S. The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus. Rheumatology (Oxford). 2022 Aug 3;61(8):3329-3340. doi: 10.1093/rheumatology/keab920. PubMed 34897375 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in May 2018, 23 months.

Results were first posted in Jun 2021, 3 years after primary completion. A results delay was requested in Jun 2019.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 23 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2016
First posted
Jun 17, 2016
StartActual
Jun 2, 2016
Primary completionActual
May 31, 2018
CompletionActual
Nov 19, 2018
Results delay requested
Jun 19, 2019
Results first posted
Jun 30, 2021
Last update
Jun 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02804763
Responsible party
Sponsor
First posted
Jun 17, 2016
Start date
Jun 2, 2016
Primary completion
May 31, 2018
Completion
Nov 19, 2018
Results posted
Jun 30, 2021
Last update
Jun 30, 2021

Study contacts

UCB Cares
study director · +1 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapirolizumab pegol

Start the discussion